Educational webinar: New treatments for preventing chronic kidney disease progression
In recent years a number of important trials in chronic kidney disease have been completed that are already changing practice and improving outcomes for patients. This webinar was a unique opportunity to hear directly from Investigators across key trials. The recent presentation by Prof Hiddo Heerspink of DAPA-CKD is generating a great deal of anticipation in the clinical community as the first large outcome trial to test the effectiveness of an SGLT2 inhibitor in chronic kidney disease. This anticipation presented a good opportunity to evaluate the overall evidence for the SGLT2 inhibitors class on kidney and cardiovascular outcomes.
• Prof Hiddo Lambers Heerspink, DAPA-CKD Trial Steering Committee Co-Chair
• Prof Vlado Perkovic, A/Prof Meg Jardine, CREDENCE Trial Steering Committee Chair and Member
• Dr Clare Arnott, cardiologist and SGLT2 inhibitor meta-analysis author
Convened and chaired by A/Prof Meg Jardine, CREDENCE Trial Steering Committee Member